Introduction

Triple negative breast cancer has long been described as hard to treat and fast moving, but this year's data, much of it long-term follow-up on treatments already reshaping practice, continues to build real momentum. The clearest story is durability: pembrolizumab's benefit in early-stage disease is holding up at nearly eight years. The newer story is expansion: antibody-drug conjugates paired with immunotherapy are extending gains into the first-line metastatic setting.

KEYNOTE-522: Pembrolizumab's Benefit Holds at Nearly Eight Years

KEYNOTE-522 established perioperative pembrolizumab (added to neoadjuvant chemotherapy, continued as adjuvant monotherapy after surgery) as standard of care for high-risk, early-stage triple negative breast cancer. The final analysis, presented this year at a median follow-up of 93.8 months, close to eight years, confirms that benefit rather than eroding it over time.

The 7-year event-free survival rate was 78.3 percent with pembrolizumab versus 69.8 percent with placebo, and the 7-year overall survival rate was 85.1 percent versus 77.2 percent, both differences holding up statistically. Benefit was consistent whether patients had achieved a pathologic complete response or not, though it was especially meaningful in patients who did not achieve a complete response, a group known to otherwise carry a worse prognosis: pembrolizumab shifted many of these patients toward a lower residual cancer burden score, which itself predicts better long-term survival. Immune-related adverse events of any grade were more common with pembrolizumab (35.0 percent versus 13.1 percent), and 7.7 percent of patients discontinued adjuvant pembrolizumab due to toxicity, but no new safety signals emerged with this additional follow-up.

HELEN-Trio 011: A Chinese Alternative Using a Non-Anthracycline Backbone

A separate, China-based neoadjuvant trial, HELEN-Trio 011 (NCT05475678), tested camrelizumab, an anti-PD-1 antibody, added to docetaxel and carboplatin (a non-anthracycline chemotherapy backbone) in 369 patients with previously untreated stage II-III triple negative breast cancer across 14 hospitals in China. Randomization was 2:1. In the modified intention-to-treat population, the pathologic complete response rate was 57.5 percent with camrelizumab plus chemotherapy versus 45.4 percent with chemotherapy alone, an absolute difference of 12.2 percentage points that reached statistical significance. The benefit was clearer in the PD-L1-positive subgroup (CPS ≥1: 69.8 percent versus 51.9 percent, a significant 17.9 percentage point difference) than in the PD-L1-negative subgroup (CPS <1: 37.8 percent versus 28.1 percent, a 9.7 percentage point difference that did not reach statistical significance, with a confidence interval crossing zero). The trial was not powered to report disease-free survival at this data cutoff. Safety was manageable: grade 3 or higher treatment-related adverse events occurred in 24.8 percent of the camrelizumab-chemotherapy group versus 21.8 percent of the chemotherapy-alone group, with no treatment-related deaths, and reactive capillary hemangiomas, a distinctive but generally mild skin finding specific to camrelizumab, were noted without being a major clinical problem.

Older patients or those who prefer to avoid anthracyclines, given their association with cardiotoxicity and secondary malignancy risk that increases with age, may particularly benefit from this non-anthracycline approach if it is confirmed in further trials; a US counterpart trial exploring immunotherapy without an anthracycline backbone is currently enrolling. (Note: some specifics of this trial's design, including whether it was placebo-controlled, could not be independently verified against the presentation slides and should be confirmed before this section is finalized.)

ASCENT-03 and ASCENT-04: Sacituzumab Govitecan Moves to First Line

The combination of antibody-drug conjugates with immunotherapy has been a major theme in metastatic triple negative breast cancer over the past decade, and two companion trials now support moving sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, into first-line treatment.

ASCENT-04 tested sacituzumab govitecan plus pembrolizumab against chemotherapy plus pembrolizumab in previously untreated, PD-L1-positive (CPS ≥10) metastatic triple negative breast cancer, replacing the prior standard backbone from KEYNOTE-355. This year's update reported additional endpoints, including progression-free survival on next line of therapy (PFS2), a surrogate that helps compensate for the fact that a high rate of crossover to sacituzumab govitecan in the control arm can otherwise obscure an overall survival benefit. Despite that crossover, PFS2 favored the sacituzumab govitecan arm by a 33 percent risk reduction, and nearly twice as many patients on that arm remained on study treatment at data cutoff (43 percent versus 22 percent). Biomarker analyses, including HER2-low status and BRCA mutation status (though only around 39 patients had a BRCA mutation, a caveat worth remembering when applying this to individual patients), favored sacituzumab govitecan across subgroups.

ASCENT-03 tested sacituzumab govitecan monotherapy against chemotherapy in patients ineligible for immunotherapy (PD-L1 negative or otherwise unable to receive a checkpoint inhibitor), also in the first-line metastatic setting. Median progression-free survival was 9.7 months with sacituzumab govitecan versus 6.9 months with chemotherapy, a 38 percent reduction in the risk of progression or death, with response rates around 50 percent in both arms and overall survival data still immature.

Two practical points from these trials matter for sequencing decisions: overall survival is becoming a difficult primary endpoint to interpret given how routinely patients cross over to effective second-line options in modern trial designs, making surrogate endpoints like PFS2 increasingly important; and drug order appears to matter, since patients tend to have long response durations to their first-line agent, arguing for using the most effective available drug as early as possible rather than saving it for later.

For Patients

Triple negative breast cancer describes tumors that lack the estrogen receptor, progesterone receptor, and HER2 protein that other breast cancer treatments target, which historically limited options to chemotherapy alone. The developments described here represent two different kinds of progress: pembrolizumab added to chemotherapy before and after surgery continues to meaningfully improve long-term survival in earlier-stage disease, now confirmed at nearly eight years of follow-up, and an antibody-drug conjugate called sacituzumab govitecan, sometimes combined with immunotherapy, is becoming a new first-line option once the cancer has spread. Patients starting first-line treatment for metastatic triple negative breast cancer should ask whether PD-L1 testing has been done, since it affects which of these approaches applies to their specific tumor.

Key Takeaways

  • KEYNOTE-522's final analysis at nearly 8 years confirms durable event-free and overall survival benefit with perioperative pembrolizumab in high-risk, early-stage triple negative breast cancer, with the largest relative benefit in patients who did not achieve a pathologic complete response.

  • HELEN-Trio 011, a Chinese trial of camrelizumab with a non-anthracycline chemotherapy backbone, significantly improved pathologic complete response overall (57.5% vs 45.4%) and in PD-L1-positive disease, though the benefit in PD-L1-negative disease did not reach statistical significance; it may still offer an option for patients who want to avoid anthracycline-related toxicity, pending confirmatory data.

  • ASCENT-04 (sacituzumab govitecan plus pembrolizumab) and ASCENT-03 (sacituzumab govitecan monotherapy) both support moving this antibody-drug conjugate into first-line treatment for metastatic triple negative breast cancer, in PD-L1-positive and PD-L1-negative/ineligible populations respectively.

  • High crossover rates in modern trial designs are making surrogate endpoints like PFS2 increasingly important for interpreting whether a first-line treatment truly extends survival.

  • Sequencing matters: using the most effective available drug as early as possible, rather than reserving it for later lines, appears to matter given how long responses last with first-line therapy.

References

  1. Schmid P, Cortes J, Dent R, et al. Neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for high-risk early-stage TNBC: final analysis of the phase 3 KEYNOTE-522 study. J Clin Oncol. 2026.

  2. Liu Z, et al. Efficacy and safety of camrelizumab combined with docetaxel and carboplatin as neoadjuvant therapy for triple-negative breast cancer: the HELEN-Trio 011 randomized clinical trial. J Clin Oncol. 2026;44(suppl 16):abstr 1009. Presented at the 2026 ASCO Annual Meeting.

  3. Tolaney SM, et al. Sacituzumab govitecan plus pembrolizumab in previously untreated PD-L1-positive metastatic triple-negative breast cancer (ASCENT-04/KEYNOTE-D19). Presented ASCO 2026.

  4. Cortés JC, Bardia A, Punie K, et al. Sacituzumab govitecan versus chemotherapy in previously untreated advanced triple-negative breast cancer unable to receive PD-(L)1 inhibitors (ASCENT-03). N Engl J Med. 2025.